{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T08:55:00Z","timestamp":1794473700460,"version":"4.9.1"},"reference-count":84,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner-Fresenius-Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.pnpbp.2026.111955","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:42:08Z","timestamp":1790869328000},"page":"111955","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["From immune dysregulation to precision immunotherapy in psychiatric disorders: A clinical-readiness framework for biomarkers and trials"],"prefix":"10.1016","volume":"150","author":[{"given":"Anna","family":"Fleischer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Schrader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Ku","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pnpbp.2026.111955_bb0005","series-title":"Details Omitted for Double-Anonymized Reviewing","author":"Anonymous","year":"2024"},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111955_bb0010","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1136\/jnnp-2019-320912","article-title":"Efficacy and safety of anti-inflammatory agents for the treatment of major depressive disorder: a systematic review and meta-analysis of randomised controlled trials","volume":"91","author":"Bai","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111955_bb0015","doi-asserted-by":"crossref","DOI":"10.1017\/neu.2025.10050","article-title":"Aspirin and atorvastatin augmentation treatment in patients with major affective disorders and inflammatory dysregulation: a 12-week randomised placebo-controlled study","volume":"38","author":"Bai","year":"2026","journal-title":"Acta Neuropsychiatr."},{"key":"10.1016\/j.pnpbp.2026.111955_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2019.172838","article-title":"Efficacy of infliximab in treatment-resistant depression: a systematic review and meta-analysis","volume":"188","author":"Bavaresco","year":"2020","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.pnpbp.2026.111955_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2026.106806","article-title":"An umbrella review of inflammatory biomarkers and their relationship to treatment response in MDD","volume":"188","author":"Baxter","year":"2026","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.pnpbp.2026.111955_bb0030","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jpsychires.2022.12.003","article-title":"Rituximab as an adjunctive treatment for schizophrenia spectrum disorder or obsessive-compulsive disorder: two open-label pilot studies on treatment-resistant patients","volume":"158","author":"Bejerot","year":"2023","journal-title":"J. Psychiatr. Res."},{"issue":"5","key":"10.1016\/j.pnpbp.2026.111955_bb0035","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/jamapsychiatry.2025.0033","article-title":"Circulating blood-based proteins in psychopathology and cognition: a mendelian randomization study","volume":"82","author":"Bhattacharyya","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111955_bb0040","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2024.1465291","article-title":"Mendelian randomization analysis of causal and druggable circulating inflammatory proteins in schizophrenia","volume":"15","author":"Cao","year":"2024","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111955_bb0045","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.bbi.2023.08.001","article-title":"Predictors of successful anti-inflammatory drug trials in patients with schizophrenia: a meta-regression and critical commentary","volume":"114","author":"Chandra","year":"2023","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.pnpbp.2026.111955_bb0050","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.bbi.2023.07.023","article-title":"TSPO PET brain inflammation imaging: a transdiagnostic systematic review and meta-analysis of 156 case-control studies","volume":"113","author":"De Picker","year":"2023","journal-title":"Brain Behav. Immun."},{"issue":"11","key":"10.1016\/j.pnpbp.2026.111955_bb0055","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S2215-0366(18)30345-6","article-title":"The benefit of minocycline on negative symptoms of schizophrenia in patients with recent-onset psychosis (BeneMin): a randomised, double-blind, placebo-controlled trial","volume":"5","author":"Deakin","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111955_bb0060","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2024.1407529","article-title":"Efficacy and acceptability of anti-inflammatory agents in major depressive disorder: a systematic review and meta-analysis","volume":"15","author":"Du","year":"2024","journal-title":"Front. Psychiatry"},{"issue":"9","key":"10.1016\/j.pnpbp.2026.111955_bb0065","doi-asserted-by":"crossref","first-page":"5049","DOI":"10.1007\/s10787-025-01908-6","article-title":"Efficacy and safety of celecoxib in schizophrenia: a systematic review and meta-analysis of randomized controlled trials","volume":"33","author":"Farag","year":"2025","journal-title":"Inflammopharmacology"},{"issue":"3","key":"10.1016\/j.pnpbp.2026.111955_bb0070","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/WCO.0000000000001259","article-title":"Central nervous system adverse events of immune checkpoint inhibitors","volume":"37","author":"Farina","year":"2024","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.pnpbp.2026.111955_bb0075","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1038\/mp.2015.168","article-title":"Inflammation is associated with decreased functional connectivity within corticostriatal reward circuitry in depression","volume":"21","author":"Felger","year":"2016","journal-title":"Mol. Psychiatry"},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111955_bb0080","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1001\/jamaneurol.2022.4251","article-title":"Autoimmune encephalitis misdiagnosis in adults","volume":"80","author":"Flanagan","year":"2023","journal-title":"JAMA Neurol."},{"issue":"3","key":"10.1016\/j.pnpbp.2026.111955_bb0085","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/s41380-022-01919-7","article-title":"Peripheral blood cellular immunophenotype in depression: a systematic review and meta-analysis","volume":"28","author":"Foley","year":"2023","journal-title":"Mol. Psychiatry"},{"issue":"3","key":"10.1016\/j.pnpbp.2026.111955_bb0090","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-067944","article-title":"Protocol for the psychosis immune mechanism stratified medicine (PIMS) trial: a randomised double-blind placebo-controlled trial of single-dose tocilizumab in patients with psychosis","volume":"13","author":"Foley","year":"2023","journal-title":"BMJ Open"},{"key":"10.1016\/j.pnpbp.2026.111955_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.psyneuen.2024.107008","article-title":"A novel biomarker of interleukin 6 activity and clinical and cognitive outcomes in depression","volume":"164","author":"Foley","year":"2024","journal-title":"Psychoneuroendocrinology"},{"issue":"8","key":"10.1016\/j.pnpbp.2026.111955_bb0100","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1001\/jamapsychiatry.2026.1053","article-title":"Interleukin 6 as a treatment target for depression: a proof-of-concept randomized clinical trial","volume":"83","author":"Foley","year":"2026","journal-title":"JAMA Psychiatry"},{"issue":"5","key":"10.1016\/j.pnpbp.2026.111955_bb0105","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jaci.2020.07.025","article-title":"Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies","volume":"146","author":"Freyer","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111955_bb0110","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1146\/annurev-clinpsy-081122-013201","article-title":"Immune dysfunction in schizophrenia spectrum disorders","volume":"20","author":"Gangadin","year":"2024","journal-title":"Annu. Rev. Clin. Psychol."},{"issue":"3","key":"10.1016\/j.pnpbp.2026.111955_bb0115","doi-asserted-by":"crossref","DOI":"10.1212\/CPJ.0000000000200155","article-title":"Autoimmune encephalitis consensus criteria: lessons learned from real-world practice","volume":"13","author":"Gelfand","year":"2023","journal-title":"Neurol. Clin. Pract."},{"key":"10.1016\/j.pnpbp.2026.111955_bb0120","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1628765","article-title":"Corticosteroid-induced manic and\/or psychotic symptoms: a systematic review","volume":"16","author":"Gostoli","year":"2025","journal-title":"Front. Pharmacol."},{"issue":"4","key":"10.1016\/j.pnpbp.2026.111955_bb0125","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1474-4422(15)00401-9","article-title":"A clinical approach to diagnosis of autoimmune encephalitis","volume":"15","author":"Graus","year":"2016","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.pnpbp.2026.111955_bb0130","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.bbi.2015.06.001","article-title":"Cumulative meta-analysis of interleukins 6 and 1\u03b2, tumour necrosis factor \u03b1 and C-reactive protein in patients with major depressive disorder","volume":"49","author":"Haapakoski","year":"2015","journal-title":"Brain Behav. Immun."},{"issue":"6","key":"10.1016\/j.pnpbp.2026.111955_bb0135","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1017\/cjn.2024.16","article-title":"Canadian consensus guidelines for the diagnosis and treatment of autoimmune encephalitis in adults","volume":"51","author":"Hahn","year":"2024","journal-title":"Can. J. Neurol. Sci."},{"issue":"12","key":"10.1016\/j.pnpbp.2026.111955_bb0140","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1038\/npp.2011.132","article-title":"The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis","volume":"36","author":"Hannestad","year":"2011","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111955_bb0145","doi-asserted-by":"crossref","first-page":"8","DOI":"10.24869\/psyd.2023.8","article-title":"Monoclonal antibody therapy in autoantibody-associated psychotic disorders and schizophrenia: narrative review of past and current clinical trials","volume":"35","author":"Hansen","year":"2023","journal-title":"Psychiatr. Danub."},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111955_bb0150","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/s41398-023-02570-8","article-title":"Network analysis of inflammation and symptoms in recent onset schizophrenia and the influence of minocycline during a clinical trial","volume":"13","author":"Herniman","year":"2023","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111955_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.psyneuen.2023.106368","article-title":"Cross-trait genome-wide association analysis of C-reactive protein level and psychiatric disorders","volume":"157","author":"Hindley","year":"2023","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.pnpbp.2026.111955_bb0160","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.bbi.2021.11.019","article-title":"Inflammatory subtypes in antipsychotic-na\u00efve first-episode schizophrenia are associated with altered brain morphology and topological organization","volume":"100","author":"Hoang","year":"2022","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.pnpbp.2026.111955_bb0165","article-title":"Prednisolone add-on in early phase schizophrenia: a randomized, double-blind, placebo-controlled pilot study","volume":"48","author":"Hoprekstad","year":"2025","journal-title":"Brain Behav. Immun. Health"},{"key":"10.1016\/j.pnpbp.2026.111955_bb0170","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.bbi.2024.07.037","article-title":"Sex differences in the inflammation-depression link: a systematic review and meta-analysis","volume":"121","author":"Jarkas","year":"2024","journal-title":"Brain Behav. Immun."},{"issue":"2","key":"10.1016\/j.pnpbp.2026.111955_bb0175","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/mp.2016.167","article-title":"Antidepressant activity of anti-cytokine treatment: a systematic review and meta-analysis of clinical trials of chronic inflammatory conditions","volume":"23","author":"Kappelmann","year":"2018","journal-title":"Mol. Psychiatry"},{"issue":"8","key":"10.1016\/j.pnpbp.2026.111955_bb0180","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/s41582-025-01112-8","article-title":"Neurological complications of CAR T cell therapy for cancers","volume":"21","author":"Karschnia","year":"2025","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.pnpbp.2026.111955_bb0185","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/s41591-020-0806-7","article-title":"A randomized proof-of-mechanism trial applying the \u2018fast-fail\u2019 approach to evaluating \u03ba-opioid antagonism as a treatment for anhedonia","volume":"26","author":"Krystal","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.pnpbp.2026.111955_bb0190","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.bbi.2024.09.005","article-title":"Low-dose interleukin-2 in patients with bipolar depression: a phase 2 randomised double-blind placebo-controlled trial","volume":"123","author":"Leboyer","year":"2025","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.pnpbp.2026.111955_bb0195","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.bbi.2020.04.063","article-title":"Efficacy of adjunctive infliximab vs. placebo in the treatment of anhedonia in bipolar I\/II depression","volume":"88","author":"Lee","year":"2020","journal-title":"Brain Behav. Immun."},{"issue":"11","key":"10.1016\/j.pnpbp.2026.111955_bb0200","doi-asserted-by":"crossref","first-page":"4722","DOI":"10.1038\/s41380-022-01784-4","article-title":"The serum metabolomic profile of a distinct, inflammatory subtype of acute psychosis","volume":"27","author":"Lennox","year":"2022","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111955_bb0205","article-title":"Circulating inflammatory cytokines influencing schizophrenia: a mendelian randomization study","volume":"15","author":"Li","year":"2024","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111955_bb0210","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.bbi.2024.10.019","article-title":"Immunophenotyping schizophrenia subtypes stratified by antipsychotic response","volume":"123","author":"Li","year":"2025","journal-title":"Brain Behav. Immun."},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111955_bb0215","article-title":"Efficacy and safety of anti-inflammatory drug-assisted treatment of symptoms in patients with schizophrenia: a meta-analysis","volume":"26","author":"Li","year":"2026","journal-title":"BMC Psychiatry"},{"issue":"6","key":"10.1016\/j.pnpbp.2026.111955_bb0220","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1038\/s41380-026-03450-5","article-title":"Neuroinflammation: an unfortunate term to describe schizophrenia","volume":"31","author":"Llorca-Bof\u00ed","year":"2026","journal-title":"Mol. Psychiatry"},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111955_bb0225","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1176\/appi.ajp.20241115","article-title":"Effect of anti-inflammatory treatment on depressive symptom severity and anhedonia in depressed individuals with elevated inflammation: systematic review and meta-analysis of randomized controlled trials","volume":"183","author":"Mac Giollabhui","year":"2026","journal-title":"Am. J. Psychiatry"},{"issue":"8","key":"10.1016\/j.pnpbp.2026.111955_bb0230","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1001\/jamapsychiatry.2019.0779","article-title":"Efficacy of adjunctive infliximab vs placebo in the treatment of adults with bipolar I\/II depression: a randomized clinical trial","volume":"76","author":"McIntyre","year":"2019","journal-title":"JAMA Psychiatry"},{"issue":"19","key":"10.1016\/j.pnpbp.2026.111955_bb0235","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1161\/CIRCULATIONAHA.120.053318","article-title":"Treatment effects of interleukin-6 receptor antibodies for modulating the systemic inflammatory response after out-of-hospital cardiac arrest (the IMICA trial): a double-blinded, placebo-controlled, single-center, randomized, clinical trial","volume":"143","author":"Meyer","year":"2021","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.pnpbp.2026.111955_bb0240","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1176\/appi.ajp.20250289","article-title":"Advancing an inflammatory subtype of major depression","volume":"182","author":"Miller","year":"2025","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111955_bb0245","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/nri.2015.5","article-title":"The role of inflammation in depression: from evolutionary imperative to modern treatment target","volume":"16","author":"Miller","year":"2016","journal-title":"Nat. Rev. Immunol."},{"issue":"7","key":"10.1016\/j.pnpbp.2026.111955_bb0250","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.biopsych.2011.04.013","article-title":"Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects","volume":"70","author":"Miller","year":"2011","journal-title":"Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111955_bb0255","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/pcn.13302","article-title":"Secondary mania induced by TNF-\u03b1 inhibitors: a systematic review","volume":"76","author":"Miola","year":"2022","journal-title":"Psychiatry Clin. Neurosci."},{"issue":"2","key":"10.1016\/j.pnpbp.2026.111955_bb0260","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1093\/brain\/awaf455","article-title":"Immune alterations in schizophrenia and the effects of a therapeutic antibody: a neuroimaging study","volume":"149","author":"Mizuno","year":"2026","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.pnpbp.2026.111955_bb0265","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/YIC.0000000000000399","article-title":"Risperidone combination therapy with adalimumab for treatment of chronic schizophrenia: a randomized, double-blind, placebo-controlled clinical trial","volume":"37","author":"Motamed","year":"2022","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2026.111955_bb0270","author":"National Institute for Health and Care Excellence"},{"issue":"12","key":"10.1016\/j.pnpbp.2026.111955_bb0275","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1017\/S0033291719001454","article-title":"Prevalence of low-grade inflammation in depression: a systematic review and meta-analysis of CRP levels","volume":"49","author":"Osimo","year":"2019","journal-title":"Psychol. Med."},{"issue":"11","key":"10.1016\/j.pnpbp.2026.111955_bb0280","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.biopsych.2025.11.009","article-title":"Lessons from clinical trials of immunomodulatory drugs in psychiatric disorders","volume":"99","author":"Pak","year":"2026","journal-title":"Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111955_bb0285","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.bpsgos.2022.01.003","article-title":"Assessing the evidence for causal associations between body mass index, C-reactive protein, depression, and reported trauma using mendelian randomization","volume":"3","author":"Palmos","year":"2023","journal-title":"Biol. Psychiatry Glob. Open Sci."},{"key":"10.1016\/j.pnpbp.2026.111955_bb0290","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.genhosppsych.2024.05.001","article-title":"Statins as an adjuvant therapy for patients with schizophrenia: an up-to-date systematic review and meta-analysis","volume":"89","author":"Peng","year":"2024","journal-title":"Gen. Hosp. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111955_bb0295","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.bbi.2024.02.019","article-title":"Low-dose interleukin 2 antidepressant potentiation in unipolar and bipolar depression: safety, efficacy, and immunological biomarkers","volume":"118","author":"Poletti","year":"2024","journal-title":"Brain Behav. Immun."},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111955_bb0300","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S2215-0366(19)30290-1","article-title":"Autoimmune psychosis: an international consensus on an approach to the diagnosis and management of psychosis of suspected autoimmune origin","volume":"7","author":"Pollak","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111955_bb0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbi.2026.106874","article-title":"Inflammatory protein markers and treatment outcomes across mood and psychotic disorders: a systematic review and meta-analysis","volume":"138","author":"Possidente","year":"2026","journal-title":"Brain Behav. Immun."},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111955_bb0310","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1001\/2013.jamapsychiatry.4","article-title":"A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers","volume":"70","author":"Raison","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111955_bb0315","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.schres.2025.04.024","article-title":"Autoimmune psychosis: psychopathological patterns and outcome after immunotherapy","volume":"281","author":"Ramirez-Bermudez","year":"2025","journal-title":"Schizophr. Res."},{"issue":"3","key":"10.1016\/j.pnpbp.2026.111955_bb0320","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.23nr15243","article-title":"Immune-targeted therapies for depression: current evidence for antidepressant effects of monoclonal antibodies","volume":"85","author":"Rizk","year":"2024","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111955_bb0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2022.148190","article-title":"Linking nervous and immune systems in psychiatric illness: a meta-analysis of the kynurenine pathway","volume":"1800","author":"Sales","year":"2023","journal-title":"Brain Res."},{"issue":"6","key":"10.1016\/j.pnpbp.2026.111955_bb0330","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1176\/appi.ajp.20240142","article-title":"Systemic inflammation and anhedonic responses to an inflammatory challenge in adults with major depressive disorder: a randomized controlled trial","volume":"182","author":"Savitz","year":"2025","journal-title":"Am. J. Psychiatry"},{"issue":"6","key":"10.1016\/j.pnpbp.2026.111955_bb0335","article-title":"Infliximab-induced depression and suicidal behavior in adolescent with Crohn\u2019s disease: case report and review of literature","volume":"4","author":"Shayowitz","year":"2019","journal-title":"Pediatr. Qual Saf."},{"issue":"5","key":"10.1016\/j.pnpbp.2026.111955_bb0340","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0280612","article-title":"Inflammatory biomarkers and perinatal depression: a systematic review","volume":"19","author":"Silva-Fernandes","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.pnpbp.2026.111955_bb0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2023.110763","article-title":"An inflamed subtype of difficult-to-treat depression","volume":"125","author":"Suneson","year":"2023","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111955_bb0350","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.bbi.2024.02.029","article-title":"Omega-3 fatty acids for inflamed depression - a match\/mismatch study","volume":"118","author":"Suneson","year":"2024","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.pnpbp.2026.111955_bb0355","article-title":"Immunomodulatory treatment may change functional and structural brain imaging in severe mental disorders","volume":"41","author":"Thunberg","year":"2024","journal-title":"Brain Behav. Immun. Health"},{"issue":"4","key":"10.1016\/j.pnpbp.2026.111955_bb0360","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1038\/s41380-024-02751-x","article-title":"A randomized proof-of-mechanism trial of TNF antagonism for motivational deficits and related corticostriatal circuitry in depressed patients with high inflammation","volume":"30","author":"Treadway","year":"2025","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111955_bb0365","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1038\/s41591-026-04465-9","article-title":"Efficacy and target engagement of dopamine agonist pramipexole for anhedonic depression: a randomized placebo-controlled trial","volume":"32","author":"Ventorp","year":"2026","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111955_bb0370","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1186\/s12888-023-05081-4","article-title":"Causal role of immune cells in schizophrenia: mendelian randomization (MR) study","volume":"23","author":"Wang","year":"2023","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111955_bb0375","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.schres.2024.02.001","article-title":"Inflammatory cerebrospinal fluid markers in schizophrenia spectrum disorders: a systematic review and meta-analysis of 69 studies with 5710 participants","volume":"266","author":"Warren","year":"2024","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.pnpbp.2026.111955_bb0380","article-title":"Efficacy of inflammation-based stratification for add-on celecoxib or minocycline in major depressive disorder: protocol of the INSTA-MD double-blind placebo-controlled randomised clinical trial","volume":"41","author":"Wessa","year":"2024","journal-title":"Brain Behav. Immun. Health"},{"issue":"6","key":"10.1016\/j.pnpbp.2026.111955_bb0385","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1038\/s41380-019-0471-8","article-title":"Effects of immunomodulatory drugs on depressive symptoms: a mega-analysis of randomized, placebo-controlled clinical trials in inflammatory disorders","volume":"25","author":"Wittenberg","year":"2020","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111955_bb0390","author":"World Medical Association"},{"key":"10.1016\/j.pnpbp.2026.111955_bb0395","doi-asserted-by":"crossref","DOI":"10.1177\/20451253241227772","article-title":"Monoclonal antibody precision therapy targeting inflammation for bipolar disorder: a narrative review","volume":"14","author":"Wu","year":"2024","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2026.111955_bb0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajp.2022.103394","article-title":"Comparative efficacy, acceptability, and tolerability of adjunctive anti-inflammatory agents on bipolar disorder: a systemic review and network meta-analysis","volume":"80","author":"Xu","year":"2023","journal-title":"Asian J. Psychiatr."},{"key":"10.1016\/j.pnpbp.2026.111955_bb0405","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.bbi.2024.08.048","article-title":"The inflammatory underpinning of depression: an historical perspective","volume":"122","author":"Yirmiya","year":"2024","journal-title":"Brain Behav. Immun."},{"issue":"11","key":"10.1016\/j.pnpbp.2026.111955_bb0410","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1001\/jamapsychiatry.2024.2185","article-title":"Inflammatory biomarkers and risk of psychiatric disorders","volume":"81","author":"Zeng","year":"2024","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111955_bb0415","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2023.110740","article-title":"Peripheral cytokine levels across psychiatric disorders: a systematic review and network meta-analysis","volume":"125","author":"Zhang","year":"2023","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111955_bb0420","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.bbi.2024.11.033","article-title":"Depression with immuno-metabolic dysregulation: testing pragmatic criteria to stratify patients","volume":"124","author":"Zwiep","year":"2025","journal-title":"Brain Behav. Immun."}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584626003532?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584626003532?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T19:37:32Z","timestamp":1793475452000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584626003532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":84,"alternative-id":["S0278584626003532"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2026.111955","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From immune dysregulation to precision immunotherapy in psychiatric disorders: A clinical-readiness framework for biomarkers and trials","name":"articletitle","label":"Article Title"},{"value":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pnpbp.2026.111955","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"111955"}}